3/27
10:26 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $104.00 to $117.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $104.00 to $117.00. They now have an "overweight" rating on the stock.
3/19
05:00 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3/17
12:32 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Piper Sandler from $140.00 to $115.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Piper Sandler from $140.00 to $115.00. They now have an "overweight" rating on the stock.
2/26
08:58 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
2/24
04:30 pm
rare
Ultragenyx to Participate at Investor Conferences in March
Low
Report
Ultragenyx to Participate at Investor Conferences in March
2/19
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/18
09:11 am
rare
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) [Yahoo! Finance]
Low
Report
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) [Yahoo! Finance]
2/18
08:00 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $121.00 to $136.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $121.00 to $136.00. They now have a "buy" rating on the stock.
2/18
08:00 am
rare
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Low
Report
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
2/15
09:39 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
2/14
08:07 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
2/14
02:37 am
rare
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
Medium
Report
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
2/14
01:53 am
rare
Ultragenyx: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Ultragenyx: Q4 Earnings Snapshot [Yahoo! Finance]
2/13
10:01 pm
rare
Ultragenyx Pharmaceutical Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Medium
Report
Ultragenyx Pharmaceutical Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/13
06:07 pm
rare
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update [Yahoo! Finance]
Low
Report
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update [Yahoo! Finance]
2/13
04:01 pm
rare
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Low
Report
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2/6
04:30 pm
rare
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
Low
Report
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
2/5
10:24 pm
rare
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductio
Low
Report
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductio
2/5
08:00 am
rare
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductio
Low
Report
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductio
1/22
11:24 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
1/17
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/13
10:30 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Piper Sandler from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Piper Sandler from $135.00 to $140.00. They now have an "overweight" rating on the stock.
1/13
10:04 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock, up previously from $46.00.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock, up previously from $46.00.
1/12
11:00 am
rare
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Medium
Report
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
1/6
04:30 pm
rare
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference